185 related articles for article (PubMed ID: 36142742)
1. Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders.
Piccoli T; Blandino V; Maniscalco L; Matranga D; Graziano F; Guajana F; Agnello L; Lo Sasso B; Gambino CM; Giglio RV; La Bella V; Ciaccio M; Colletti T
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142742
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K
Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597
[TBL] [Abstract][Full Text] [Related]
4. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Dulewicz M; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172069
[TBL] [Abstract][Full Text] [Related]
5. The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis.
Wang Z; Yang J; Zhu W; Tang Y; Jia J
Int J Neurosci; 2022 Dec; 132(12):1245-1253. PubMed ID: 33527855
[No Abstract] [Full Text] [Related]
6. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
Barba L; Abu Rumeileh S; Bellomo G; Paolini Paoletti F; Halbgebauer S; Oeckl P; Steinacker P; Massa F; Gaetani L; Parnetti L; Otto M
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):83-86. PubMed ID: 35944974
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.
Shim KH; Kang MJ; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2022 Dec; 14(1):201. PubMed ID: 36587215
[TBL] [Abstract][Full Text] [Related]
10. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays.
Öhrfelt A; Dumurgier J; Zetterberg H; Vrillon A; Ashton NJ; Kvartsberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
Alzheimers Res Ther; 2020 Dec; 12(1):168. PubMed ID: 33353563
[TBL] [Abstract][Full Text] [Related]
11. Neurogranin as a Novel Biomarker in Alzheimer's Disease.
Agnello L; Gambino CM; Lo Sasso B; Bivona G; Milano S; Ciaccio AM; Piccoli T; La Bella V; Ciaccio M
Lab Med; 2021 Mar; 52(2):188-196. PubMed ID: 32926148
[TBL] [Abstract][Full Text] [Related]
12. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
13. Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer's Disease.
Baldacci F; Daniele S; Piccarducci R; Giampietri L; Pietrobono D; Giorgi FS; Nicoletti V; Frosini D; Libertini P; Lo Gerfo A; Petrozzi L; Donadio E; Betti L; Trincavelli ML; Siciliano G; Ceravolo R; Tognoni G; Bonuccelli U; Martini C
Mol Neurobiol; 2019 Sep; 56(9):6451-6459. PubMed ID: 30826968
[TBL] [Abstract][Full Text] [Related]
14. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
[TBL] [Abstract][Full Text] [Related]
15. The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis.
Yoong SQ; Lu J; Xing H; Gyanwali B; Tan YQ; Wu XV
Ageing Res Rev; 2021 Dec; 72():101491. PubMed ID: 34688925
[TBL] [Abstract][Full Text] [Related]
16. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia.
Álvarez I; Diez-Fairen M; Aguilar M; González JM; Ysamat M; Tartari JP; Carcel M; Alonso A; Brix B; Arendt P; Pastor P
Eur J Neurol; 2021 Apr; 28(4):1142-1152. PubMed ID: 33236496
[TBL] [Abstract][Full Text] [Related]
17. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
[TBL] [Abstract][Full Text] [Related]
19. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.
Liu W; Lin H; He X; Chen L; Dai Y; Jia W; Xue X; Tao J; Chen L
Transl Psychiatry; 2020 Apr; 10(1):125. PubMed ID: 32350238
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis.
Dulewicz M; Kulczyńska-Przybik A; Borawska R; Słowik A; Mroczko B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
